Bizarre Patents
Wearable Device For Feeding and Observing Birds and Other Flying Animals
A device for feeding and observing flying animals comprising a hat, a support mounted on the hat and extending outward from the hat, and a feeder mounted on the support.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20080305161 | INJECTABLE DEPOT FORMULATIONS AND METHODS FOR PROVIDING SUSTAINED RELEASE OF NANOPARTICLE COMPOSITIONS Pharmaceutical formulations comprising: a compound selected from the group consisting of ziprasidone, having a maximum average particle size; a carrier; and preferably at least two surface stabilizers are disclosed. The present invention also comprises methods of treati... | 12/11/2008 |
| 20080300273 | Method of Treating Abnormal Cell Growth The present invention relates to the use of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine, a novel c-Met/HGFR inhibitor, for treating abnormal cell growth in mammals. In particular, the invention provides methods ... | 12/04/2008 |
| 20080300234 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH The present invention relates to a compound of the formula 1
| |
| 20080299188 | CONTROLLED RELEASE DOSAGE FORMS COMBINING IMMEDIATE RELEASE AND SUSTAINTED RELEASE OF LOW-SOLUBILITY DRUG A controlled release dosage form comprises an immediate release portion and an enteric coated sustained release core.... | 12/04/2008 |
| 20080293801 | Solid Amorphous Dispersions of An Mtp Inhibitor For Treatment of Obesity A composition comprises a solid amorphous dispersion comprising (S)—N-{2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl}-methyl-5-[4′-(trifluoromethyl)[1,1′-biphenyl]-2-carboxamido]-1H-indole-2-carboxamide and a polymer.... | 11/27/2008 |
| 20080293769 | Polymorphs of a C-Met/Hgfr Inhibitor This invention relates to polymorphs of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositio... | 11/27/2008 |
| 20080293646 | MACROLIDES The invention relates to compounds of Formula (I): wherein R1, R2 and X are as defined herein. The invention also relates to pharmaceutical compositions and methods of treating bacterial... | 11/27/2008 |
| 20080293633 | Pharmaceutical Formulations, Methods, and Dosing Regimens for the Treatment and Prevention of Acute Coronary Syndromes The invention provides methods and formulations for treating and preventing acute coronary syndromes. The methods of the instant invention provide safe and effective doses of an Apolipoprotein A-I Milano: phospholipid complex to reduce and stabilize atherosclerotic plaq... | 11/27/2008 |
| 20080292707 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug Pharmaceutical compositions comprise a low-solubility drug adsorbed onto a high surface area substrate to form an adsorbate. The compositions in some embodiments include a concentration-enhancing polymer.... | 11/27/2008 |
| 20080287479 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE This invention provides compounds of the formula: useful in the inhibition or modulation of serine palmitoyl transferase and their use in methods of treatment or amelioration of type 2 diabetes, type 1 diabet... | 11/20/2008 |
| 20080287521 | Crystalline Forms Of [R-(R*,R*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methyl- Ethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Calcium Salt (2:1) Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, F... | 11/20/2008 |
| 20080280879 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS Compounds of the general Formula I, wherein X1, X2, X3, X4, X5, X6, X7, R1, R2, R4, R5, R6, R7, R8, R9, R... | 11/13/2008 |
| 20080280877 | Azetidines The invention relates to EP2 antagonist azetidines of formula (I) wherein Ar, R1, X, and Z are as defined herein, to their use in medicine, particularly in the treatment of endometriosis and/or ute... | 11/13/2008 |
| 20080280875 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein:
| |
| 20080269293 | PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS This invention relates to novel compounds of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof wherein Y, R1 through R9, and X1 through X7 a... | 10/30/2008 |
| 20080269111 | METHOD OF TREATING DYSLIPIDEMIC DISORDER The invention provides methods of treating or preventing a condition or disorder associated with dyslipidemia with compositions comprising apolipoprotein-sphingomyelin complexes. The methods of the invention permit reduction, by 4- to 20-fold, of the amount of apolipopr... | 10/30/2008 |
| 20080269211 | Indazole Derivatives This invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein: R1, R2, R3, A and m are each as described herein and composition... | 10/30/2008 |
| 20080269246 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER The present invention, in one aspect, relates to a method of using piperazinyl-heterocyclic compounds of the formula I, as defined below, for enhancing cognition in a mammal, including a human, for example a mammal afflicted with psychosis, autism, dementia, or mental r... | 10/30/2008 |
| 20080261995 | Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor This invention relates to the combined use of a PDE5 inhibitor and a 5-alpha reductase antagonist in the treatment of lower urinary tract symptoms (LUTS), such as urgency, frequency, nocturia and urge incontinence.... | 10/23/2008 |
| 20080262056 | Oxindole Oxazolidinones as Antibacterial Agents The present invention relates to novel oxazolidinones derivatives of oxindoles of formula I or a pharmaceutically acceptable salt thereof wherein: Y1 is CH or CF; R1 is —C1-4alkyl, optionally substituted with a fluoro atom, or R1 ... | 10/23/2008 |
| 20080249031 | CRYSTALLINE FORMS The present invention relates to crystalline forms of (3S)-3-[N—(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid (see formula I). The invention further relates to pharmaceutical compositions comprising such... | 10/09/2008 |
| 20080249094 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS The present invention relates to compounds of the Formula wherein R3, R5, R7, U, X, Y and Z are as defined. Compounds of the Formula I have activity inhibiting production of A... | 10/09/2008 |
| 20080242874 | Direct Aminolysis In some aspects, the present invention provides a method of preparing a compound of the formula (I) comprising reacting a mesylate compound of the formula (II) by direct aminolysis with a reagent comprising ammonia. The reaction is preferably carried out in a solvent, s... | 10/02/2008 |
| 20080234303 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH The present invention relates to a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein Ar is a group of formula and R1, R2, R13, A, K, M, L1, L2, X, Y1, Y 09/25/2008 | |
| 20080234252 | Compounds Useful in Therapy Compounds of formula (I), or a pharmaceutically acceptable salt, solvate, ester or amide thereof, wherein
| |
| 20080227781 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS The present invention relates to compounds of the Formula I wherein R1, R2, R3, R4, R6, R7 and A are as defined. Compounds of the Formula I ha... | 09/18/2008 |
| 20080227974 | Novel Substituted Azetidinones Novel azetidinones and pharmaceutical compositions are described, as are the methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis.... | 09/18/2008 |
| 20080221154 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE Bicyclic hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity... | 09/11/2008 |
| 20080214607 | HETEROAROMATIC QUINOLINE COMPOUNDS The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of ... | 09/04/2008 |
| 20080213375 | Drying of Drug-Containing Particles A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes, the secondary drying process utilizing a combination of vacuum, agitation, and a stripping gas.... | 09/04/2008 |
| 20080215249 | Crystallization and structure determination of beta secretase and/or beta secretase-like proteins The x-ray crystal structure of human BACE or BACE-like proteins is useful for solving the structure of other molecules or molecular complexes, and identifying and/or designing potential modifiers of human BACE activity.... | 09/04/2008 |
| 20080214651 | Crystalline forms of [R-(R*, R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) Novel crystalline forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII,... | 09/04/2008 |
| 20080207755 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders This invention relates to a method of treating certain disorders by administering a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein: R1 | |
| 20080207712 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS The present invention relates to compounds of the Formula I wherein R1, R3, R4, R5, R6 and R7 are as defined. Compounds of the Formula I have ... | 08/28/2008 |
| 20080207665 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester or salt thereof, wherein R1 and R2 independently represent hydrogen or the like; R3 represents aryl or the like; —X—Y— represents —CH 08/28/2008 | |
| 20080206257 | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor a... | 08/28/2008 |
| 20080207689 | Formamide Derivatives For The Treatment of Diseases The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds ac... | 08/28/2008 |
| 20080200490 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists This invention provides the compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 independently represent hydrogen or the like; R3 and R4 independently represents hydrogen or the like; R 08/21/2008 | |
| 20080200475 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: (I) wherein A1, A2, A3, A4, A5, A6, A7, A8, X 08/21/2008 | |
| 20080194841 | Preparation of Optically Pure Beta-Amino Acids Having Affinity for the Alpha-Delta Protein Disclosed are materials and methods for preparing optically active β-amino acids, which bind to the alpha-2-delta subunit of a calcium channel and are useful for treating pain, fibromyalgia, and a variety of psychiatric and sleep disorders. The method includes reacting... | 08/14/2008 |
